Epilepsy is a chronic heterogenous condition in which patients experience recurrent and seemingly unprovoked seizures. Epilepsy is a common condition with about 46 million people worldwide suffering active epilepsy. Despite being common, classifying, diagnosing and treating epilepsy can be difficult.
Paediatric epilepsy treatment focuses on managing clinical seizures and the optimal use of current anti-epileptic drugs (AED) may allow more patients to reduce or attain freedom from seizures. While there is an abundance of choice in AEDs, treatment is most effective when AED activity is matched to seizure type which necessitates accurate seizure classification.
The use of AEDs is ineffective in around one-third of adult epilepsy cases and so alternative methods of treating drug-resistant epilepsy are available. These include surgery, neuromodulation and a ketogenic diet.
To find out more about epilepsy visit our dedicated Learning Zone, which contains expert-led information on paediatric epilepsy, focal seizures in adults and the treatment options available.
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Related news and insights
Eton Pharmaceuticals, Inc a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has submitted a new drug application (NDA) for zonisamide oral suspension, previously known as the company’s ET 104 product candidate, to the FDA for the treatment of partial seizures in patients with epilepsy.
Aquestive Therapeutics, Inc. reported that the FDA issued a response letter (Response) dated January 10, 2020 denying Aquestive's Citizen's Petition...